Biogen拟以4.42亿美元收购创新药公司Sage剩余股份，Sage盘后涨近44%
1月11日，美国药企Biogen计划以4.42亿美元收购创新药公司Sage Therapeutics剩余的股份。这一收购交易意味着Biogen将全面控制Sage，后者以开发精神健康和神经科学领域创新疗法为主。此次交易是Biogen在精神健康领域战略扩展的一部分，旨在增强其在中枢神经系统疾病领域的地位。
此次收购预计将有助于Biogen加速推进Sage的候选药物的研发，尤其是在治疗抑郁症、神经性疾病等领域的药物。此外，Sage的部分药物候选正在进行临床试验，这对Biogen未来的发展可能带来重要推动力。
这一交易体现了生物制药行业的并购趋势，尤其是大公司通过收购创新药企来补充和拓展其产品线和研发管线。
受此消息影响，Sage盘后涨近44%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10